UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

VANTAGE SPECIALTY CHEMICALS, INC.

Petitioner,

v.

CARGILL, INCORPORATED,

Patent Owner

Case IPR2023-00589
U.S. Patent 11,248,245

DECLARATION OF DR. CASEY M. KRANING IN SUPPORT OF PATENT OWNER'S UNOPPOSED MOTION FOR *PRO HAC VICE* ADMISSION

CARGILL 2008
Vantage v. Cargill
IPR2023-00589

DECLARATION OF DR. CASEY M. KRANING IN SUPPORT OF PATENT OWNER'S MOTION FOR *PRO HAC VICE* ADMISSION

I, DR. CASEY M. KRANING, hereby declare to the following:

1. I am a member in good standing of the United States District Court for the District of Delaware and the United States Court for the Eastern District of Pennsylvania.

2. I have not been suspended or disbarred from practice before any court or administrative body.

3. I have never had an application for admission to practice before any court or administrative body denied on the basis of ethical or moral or ethical character or ethical breach.

4. No sanction or contempt citation has been imposed against me by any court or administrative body.

5. I have read and will comply with the Office Patent Trial Practice Guide and the Board's Rules of Practice for Trials set forth in Part 42, Title 37 of the Code of Federal Regulations.

6. I will be subject to the USPTO Rules of Professional Conduct set forth in 37 C.F.R. §§ 11.101 *et seq.* and disciplinary jurisdiction under 37 C.F.R. § 11.19(a).

7. I have applied for and been granted leave to appear *pro hac vice* in IPR2022-00381, IPR2021-00451, IPR2022-00617 and IPR2022-00682.

8. I have a Bachelor of Science in Chemistry, a Master of Science in Biomedical Engineering, and a Ph.D. in Biomedical Engineering, and I have personally reviewed and analyzed the patent-at-issue and Petition in this proceeding. I am also familiar with the prior art and have experience working with a technical expert on the subject matter of the patent-at-issue. Through my experience and analysis of the aforementioned documents, I have acquired substantial understanding of the underlying technological issues at stake in these proceedings.

9. I am an experienced litigation attorney with 7 years of experience representing clients in patent cases in the pharmaceutical, life sciences, consumer products, and oil and gas industries. I regularly litigate patent cases in various forums including before the United States District Court for the District of Delaware. Through my experience in patent litigation matters, I have represented clients in many phases of litigation including in drafting and responding to discovery, working with technical experts, taking depositions, drafting motions and summary judgment briefs, conducting pre-suit diligence, and working on all stages of IPRs. I have also been substantively involved in developing technical and legal arguments.

10. My biography is attached hereto as Appendix A.

11. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patents issued thereon.

Respectfully submitted,

Date: November 14, 2023

/Casey M. Kraning/

Casey M. Kraning, Ph.D.
Fish & Richardson P.C.
60 South Sixth Street
Minneapolis, MN 55402
T: 202-783-5070
F: 877-769-7945

APPENDIX A

Casey M. Kraning, Ph.D.

Associate

Wilmington, DE

302-778-8422

cmk@fr.com

Overview

About Casey

Casey Kraning, Ph.D., is a litigation associate in the Delaware office of Fish & Richardson focusing on patent litigation in district court and post-grant practice before the USPTO. She works primarily with clients in the pharmaceutical industry, but also represents clients in the life sciences, household products, and oil and gas industries. Dr. Kraning has experience in drafting discovery, working with technical experts, conducting pre-suit diligence, and working on all stages of IPRs—assisting with everything from pre-filing diligence through drafting slides for oral argument. In the pro bono sphere, Dr. Kraning has represented clients before the U.S. Citizenship and Immigration Services agency, in Delaware family court, and is currently assisting a public defender's office in obtaining discovery in an Eighth Amendment challenge brought by inmates on death row. She continues to seek new opportunities to grow and strengthen her practice.

Focus Areas

Services

- Litigation
- Post-Grant
- Hatch-Waxman

Industries

- Chemicals

- Life Sciences

Education

J.D., University of Pennsylvania Law School (2016) Managing Editor, *Penn Intellectual Property Group Online*; awarded “Best Advocate” and “Best Appellee Brief” at the Western Regional of the AIPLA Giles Rich Moot Court

Ph.D., Biomedical Engineering, Cornell University (2013) Thesis: “The Role of Force Generation in Metastatic Cancer Progression”

M.S., Biomedical Engineering, Cornell University (2012)

B.S. *summa cum laude*, Chemistry, Butler University (2008)

Insights

Publications

- “Director Vidal Issues Interim Guidance on Discretionary Denials under Fintiv,” *Fish Post-Grant Alerts* (June 27, 2022)
- “Prior art stipulations, a petitioner’s tool for addressing Fintiv Denials,” *Westlaw Journal IP* (June 13, 2022)
- “Stays Pending IPR In Del. District Courts Are Here To Stay,” *Law360* (March 12, 2022)
- “2021 Post-Grant Report,” *Fish & Richardson* (February 7, 2022)
- “2020 Post-Grant Report,” *Fish & Richardson* (January 28, 2021)
- “Biosimilars 2021 Year in Review,” *Fish Litigation Blog* (January 11, 2022)
- “The Herceptin® Battle Moves into the District Court,” *Fish Litigation Blog* (November 22, 2017)
- “PTAB Splits on Instituting Challenges to Herceptin® Patents,” *Fish Post-Grant Alerts* (August 2, 2017)
- “Pfizer Takes Aim at Herceptin® Patent at the PTAB,” *Fish Post-Grant Alerts* (July 12, 2017)
- “The Last “Cabilly” Challenge Quietly Settles,” *Fish Post-Grant Alerts* (May 25, 2017)
- “Rituxan® Patents Resurface at the PTA,” *Fish Post-Grant Alerts* (March 10, 2017)
- “Biogen Dodges IPR Bullet on Key Tysabri® Patents,” *Fish Litigation Blog* (October 20, 2016)
- “Microfabricated Collagen Tracks Facilitate Single Cell Metastatic Invasion in 3D,” *Integrative Biology*, 2013:5 606-16
- “Controlling Matrix Stiffness and Topography for the Study of Tumor Cell Migration,” *Cell Adhesion & Migration*, 2012:6 274-9

- “Methods in Cell Biology (Chapter: Quantifying Traction Stresses in Adherent Cells) Elsevier,” New York, 2012:110 139-78
- “Cellular Traction Stresses Increase with Increasing Metastatic Potential,” *PLoS One*, 2012:7(2) e32572
- “The Role of the Cytoskeleton in Cellular Force Generation in 2D and 3D Environments,” *Physical Biology*, 2011:8 015009 (selected as one of *Physical Biology*’s “Highlights of 2011”)
- “Microfabrication of an Asymmetric, Multi-layered Microdevice for Controlled Release of Orally Delivered Therapeutics,” *Lab on a Chip*, 2008:8 1042-47
- “Determination of Surface Coverage and Orientation of Reduced Cytochrome c on a Silica Surface with Polarized ATR Spectroscopy,” *J. Phys. Chem. C*, 2007:111(35) 13062-67

Speaking Engagements

- “Post-Grant for Practitioners: 2022 Mid-Year Review,” *Fish Webinar* (August 11, 2022)